Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat plus Docetaxel in Advanced NSCLC
NCT03228186Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pevonedistat in non-small cell lung cancer (NSCLC), sponsored by University of Michigan Rogel Cancer Center. Started Mar 2018; status: terminated.
02
Drugs
pevonedistat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03228186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228186.